EntreMed is a clinical-stage pharmaceutical company that develops therapeutic candidates primarily for the treatment of cancer and inflammation. Its flagship drug candidate, Panzem, is in clinical trials for cancer, as well as in preclinical development for non-oncology indications. Another product, MKC-1, is a novel cell cycle inhibitor acquired through the 2006 acquisition of Miikana Therapeutics. EntreMed has expertise in angiogenesis, cell cycle regulation and inflammation-processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. EntreMed has headquarters in Rockville, Md., and its shares trade on the NASDAQ under the symbol ENMD.